AngioDynamics, Inc. ANGO

Nasdaq · EDGAR · Updated Nov 4, 2026

AngioDynamics, Inc. (Nasdaq: ANGO) is a medical device company.

Upcoming catalysts

No catalyst is dated to the next 30 days or to an FDA action date.

Oct 8, 2026
accepted FDA approved Investigational Device Exemption (IDE) for the RELIEF study evaluating NanoKnife IRE for the treatment of benign prostatic hyperplasia.The Company received FDA approval of its IDE for the RELIEF study, a feasibility trial evaluating NanoKnife IRE for the treatment of benign prostatic hyperplasia. Filing
Oct 8, 2026
n/a The RELIEF feasibility trial will enroll 40 subjects at up to five U.S. sites with a primary endpoint measuring IPSS change at six months.The study is designed to enroll 40 subjects at up to five U.S. clinical sites, with a primary endpoint measuring change in the International Prostate Symptom Score at six months. Filing
Jan 6, 2026
approval FDA granted 510(k) clearance for a modified AlphaVac mechanical thrombectomy system.Three regulatory milestones support Mechanical Thrombectomy portfolio: Modified AlphaVac 510(k) clearance, PAVE and APEX-Return IDE approvals Filing

1 more on record.

Cash runway against each catalyst, with the company's own runway statement
Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
Expected move for each dated catalyst, from comparable past events
Phase 2 evidence behind each Phase 3 readout
Companies on the same target or class
Full catalyst list with filing sentences, deals, registered trials, Excel export